Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome-Multicenter, Real-Life Long-Term Follow-Up.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 26 12 2021
accepted: 15 03 2022
entrez: 6 5 2022
pubmed: 7 5 2022
medline: 10 5 2022
Statut: epublish

Résumé

Antiphospholipid syndrome (APS) is an acquired hypercoagulable condition associated with antiphospholipid antibody (aPL) presence. Data on re-thrombosis following APS-diagnosis are limited. This is a retrospective analysis of new thrombotic events among primary APS (pAPS) patients followed for up to 15 years in three medical centers in Israel. Among 312 primary-APS patients, 143 (46%) had new thrombotic event classified to three patterns: (1) In this real-life observation, re-thrombosis was common among pAPS patients including in those recommended to receive prophylactic therapy. Different patterns of recurrence were identified and linked with presenting symptoms, specific serological markers, APS manifestations, and comorbidities. Studies that will address interventions to prevent recurrences of APS-related events are needed.

Sections du résumé

Background
Antiphospholipid syndrome (APS) is an acquired hypercoagulable condition associated with antiphospholipid antibody (aPL) presence. Data on re-thrombosis following APS-diagnosis are limited.
Methods
This is a retrospective analysis of new thrombotic events among primary APS (pAPS) patients followed for up to 15 years in three medical centers in Israel.
Results
Among 312 primary-APS patients, 143 (46%) had new thrombotic event classified to three patterns: (1)
Conclusion
In this real-life observation, re-thrombosis was common among pAPS patients including in those recommended to receive prophylactic therapy. Different patterns of recurrence were identified and linked with presenting symptoms, specific serological markers, APS manifestations, and comorbidities. Studies that will address interventions to prevent recurrences of APS-related events are needed.

Identifiants

pubmed: 35514968
doi: 10.3389/fimmu.2022.843718
pmc: PMC9063725
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

843718

Informations de copyright

Copyright © 2022 Niznik, Rapoport, Avnery, Lubetsky, Haj Yahia, Ellis and Agmon-Levin.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Thromb Res. 2021 Feb;198:213-221
pubmed: 33485122
Clin Exp Rheumatol. 2021 Sep-Oct;39(5):1049-1055
pubmed: 33124581
Rheumatology (Oxford). 2013 Aug;52(8):1397-403
pubmed: 23315788
Blood. 2003 Mar 1;101(5):1827-32
pubmed: 12393574
Int J Cardiol. 2017 Aug 1;240:72-77
pubmed: 28385357
Blood Adv. 2017 Nov 16;1(25):2320-2324
pubmed: 29296881
Auto Immun Highlights. 2020 May 15;11(1):8
pubmed: 32467748
Ann Intern Med. 1992 Aug 15;117(4):303-8
pubmed: 1637025
Autoimmun Rev. 2016 Dec;15(12):1120-1124
pubmed: 27639837
Ann Intern Med. 2021 Oct;174(10):1420-1429
pubmed: 34516270
Int J Clin Exp Pathol. 2015 Mar 01;8(3):3204-9
pubmed: 26045841
Am J Med. 1996 May;100(5):530-6
pubmed: 8644765
Autoimmun Rev. 2020 Apr;19(4):102491
pubmed: 32084592
N Engl J Med. 1995 Apr 13;332(15):993-7
pubmed: 7885428
BJOG. 2019 Apr;126(5):656-661
pubmed: 30222236
Ann Rheum Dis. 2015 Jun;74(6):1011-8
pubmed: 24464962
Semin Thromb Hemost. 2012 Jun;38(4):339-47
pubmed: 22467528
Immunol Res. 2017 Apr;65(2):524-531
pubmed: 28215033
Lupus. 2017 Oct;26(12):1328-1332
pubmed: 28387637
J Rheumatol. 2000 Dec;27(12):2817-21
pubmed: 11128669
J Thromb Haemost. 2006 Feb;4(2):295-306
pubmed: 16420554
Autoimmun Rev. 2013 Jun;12(8):826-31
pubmed: 23219773
Lupus. 2011 Feb;20(2):206-18
pubmed: 21303837
J Thromb Haemost. 2010 Feb;8(2):237-42
pubmed: 19874470
Lupus. 2011 Feb;20(2):165-73
pubmed: 21303833
J Autoimmun. 2018 Jun;90:1-27
pubmed: 29449131
J Rheumatol. 2012 Mar;39(3):516-23
pubmed: 22247356
Arthritis Rheum. 2012 Aug;64(8):2677-86
pubmed: 22553077
Stroke. 2005 Jul;36(7):1490-4
pubmed: 15947270
Lupus. 2016 Apr;25(5):479-85
pubmed: 26657216
J Rheumatol. 2017 Aug;44(8):1165-1172
pubmed: 28572466
Thromb Haemost. 1995 Dec;74(6):1597-603
pubmed: 8772243
Semin Arthritis Rheum. 2019 Dec;49(3):464-468
pubmed: 31153708
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Ann Rheum Dis. 2019 Oct;78(10):1296-1304
pubmed: 31092409
Autoimmun Rev. 2018 Oct;17(10):1011-1021
pubmed: 30103045
Eur J Obstet Gynecol Reprod Biol. 2001 May;96(1):37-50
pubmed: 11311759
Stroke. 2018 Nov;49(11):2770-2772
pubmed: 30355196

Auteurs

Stanley Niznik (S)

Clinical Immunology, Angioedema and Allergy Unit, The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel.

Micha J Rapoport (MJ)

Department of Internal Medicine "C", Shamir Medical Center, Zerifin, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Orly Avnery (O)

Hematology Institute and Blood Bank, Meir Medical Center, Kfar Saba, Israel.

Aharon Lubetsky (A)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
The National Hemophilia Center and Thrombosis Unit, Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Ramat Gan, Israel.

Soad Haj Yahia (S)

Clinical Immunology, Angioedema and Allergy Unit, The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Martin H Ellis (MH)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Hematology Institute and Blood Bank, Meir Medical Center, Kfar Saba, Israel.

Nancy Agmon-Levin (N)

Clinical Immunology, Angioedema and Allergy Unit, The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH